new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Incyte Corporation
Incyte Corporation A Delaware Corporation
Incyte Corporationn A Delaware Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Incyte Corporation patents


      
Recent patent applications related to Incyte Corporation. Incyte Corporation is listed as an Agent/Assignee. Note: Incyte Corporation may have other listings under different names/spellings. We're not affiliated with Incyte Corporation, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Incyte Corporation-related inventors




Search recent Press Releases: Incyte Corporation-related press releases
Count Application # Date Incyte Corporation patents (updated weekly) - BOOKMARK this page
12010002252201/28/10 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
22015021069207/30/15  new patent  Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
32015019037807/09/15 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase
42015018380507/02/15 Processes and intermediates for making a jak inhibitor
52015017560406/25/15 Tricyclic heterocycles as bet protein inhibitors
62015016490006/18/15 Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
72015014834205/28/15 Bicyclic heterocycles as bet protein inhibitors
82015014834805/28/15 Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
92015014837205/28/15 Bicyclic heterocycles as bet protein inhibitors
102015014837505/28/15 Bicyclic heterocycles as bet protein inhibitors
112015013367405/14/15 Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
122015008763203/26/15 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as jak inhibitors
132015008766203/26/15 Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
142015006544703/05/15 Survival benefit in patients with solid tumors with elevated c-reactive protein levels
152015006548403/05/15 Sustained release dosage forms for a jak1 inhibitor
162015005726502/26/15 Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
172015002505601/22/15 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
182015001717301/15/15 Antibodies to human transmembrane proteins
192015001154001/08/15 Tricyclic heterocycles as bet protein inhibitors
202015000416501/01/15 Secreted proteins
212014037729212/25/14 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
222014037840012/25/14 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
232014037121612/18/14 Purinone derivatives as hm74a agonists
242014034303011/20/14 Bipyrazole derivatives as jak inhibitors
252014031596210/23/14 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase
262014027503009/18/14 Tricyclic heterocycles as bet protein inhibitors
272014027503109/18/14 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
282014027512709/18/14 Substituted heteroaryl fused derivatives as pi3k inhibitors
292014025694109/11/14 Processes and intermediates for making a jak inhibitor
302014024913209/04/14 Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
312014024208608/28/14 Polynucleotides encoding signal peptide-containing molecules
322014024330808/28/14 Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
332014024336008/28/14 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
342014022727508/14/14 Methods of treating and diagnosing pancreatitis
352014022727808/14/14 Antibodies to human signal peptide-containing proteins
362014022834608/14/14 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
372014022137908/07/14 N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
382014020021607/17/14 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
392014020022707/17/14 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
402014018753007/03/14 Aza spiro alkane derivatives as inhibitors of metalloproteases
412014017140506/19/14 Fused pyrazoles as fgfr inhibitors
422014017140906/19/14 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
432014015528806/05/14 Methods for diagnosing cancer
442014015537706/05/14 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
452014015540406/05/14 Piperazinylpiperidine derivatives as chemokine receptor antagonists
462014013535005/15/14 Sustained-release dosage forms of ruxolitinib
472014012119805/01/14 Tricyclic fused thiophene derivatives as jak inhibitors
482014012122205/01/14 Pyrimidinones as pi3k inhibitors
492014006644803/06/14 Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
502014005690602/27/14 Secreted proteins
512014005791202/27/14 Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
522014004581402/13/14 Pyrazine derivatives as fgfr inhibitors
532014003134401/30/14 Azepine inhibitors of janus kinases
542014002366301/23/14 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
552014001837401/16/14 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
562014000516601/02/14 Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
572014000521001/02/14 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
582013034515712/26/13 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
592013034522412/26/13 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
602013032451512/05/13 Imidazotriazines and imidazopyrimidines as kinase inhibitors
612013025319009/26/13 Processes for preparing jak inhibitors and related intermediate compounds
622013025319109/26/13 Processes for preparing jak inhibitors and related intermediate compounds
632013025319309/26/13 Processes for preparing jak inhibitors and related intermediate compounds
642013024378109/19/13 Signal peptide-containing proteins
652013024492709/19/13 Polynucleotides encoding signal peptide-containing molecules
662013024499909/19/13 Substituted heterocyclic compounds
672013022476908/29/13 Methods of using chemokine panec-1 antibodies
682013022555608/29/13 Azetidine and cyclobutane derivatives as jak inhibitors
692013019025007/25/13 Polynucleotides encoding human signal peptide-containing proteins
702013017759007/11/13 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
712013013768105/30/13 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
722013012324605/16/13 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
732013011623005/09/13 3-aminopyrrolidine derivatives as modulators of chemokine receptors
742013009614404/18/13 Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors
752013005894203/07/13 Human beta-adrenergic receptor kinase polypeptide and methods
762013005983503/07/13 Heterocyclylamines as pi3k inhibitors
772013006002603/07/13 Processes and intermediates for making a jak inhibitor
782013004596302/21/13 Cyclohexyl azetidine derivatives as jak inhibitors
792013001803401/17/13 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
802013001806801/17/13 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
812012032978212/27/12 Azepine inhibitors of janus kinases
822012030146411/29/12 Janus kinase inhibitors for treatment of dry eye and other eye related diseases
832012029591211/22/12 Piperazinylpiperidine derivatives as chemokine receptor antagonists
842012027080910/25/12 Human transmembrane proteins
852012012285805/17/12 Lactam compounds and their use as pharmaceuticals
862012004096402/16/12 N-substituted piperidines and their use as pharmaceuticals
872012003517202/09/12 Purinone derivatives as hm74a agonists
882012001493701/19/12 Human beta-adrenergic receptor kinase polypeptide and methods
892012001592801/19/12 Amido compounds and their use as pharmaceuticals
902011025121510/13/11 Macrocyclic compounds and their use as kinase inhibitors
912011021296709/01/11 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
922011020775408/25/11 Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
932011013678106/09/11 Imidazotriazines and imidazopyrimidines as kinase inhibitors
942011008681004/14/11 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
952011008215904/07/11 Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
962011005321703/03/11 Polynucleotides encoding signal peptide-containing molecules
972010027933311/04/10 Methods of treatment with antibodies to a chemokine expressed in inflamed adenoid
982010025611410/07/10 Amido compounds and their use as pharmaceuticals
992010024067109/23/10 Substituted heterocyclic compounds
1002010020303908/12/10 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
1012010019080407/29/10 Macrocyclic compounds and their use as kinase inhibitors
1022010017390107/08/10 Substituted heterocyclic compounds
1032010013740106/03/10 2-methylprop anamides and their use as pharmaceuticals
1042010011950305/13/10 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
1052010009961704/22/10 Secreted proteins
1062009031840512/24/09 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
1072009029194611/26/09 Lactam compounds and their use as pharmaceuticals
1082009028677411/19/09 Purinone derivatives as hm74a agonists
1092009028677811/19/09 Macrocyclic compounds and their use as kinase inhibitors
1102009027468011/05/09 Human phospholipases
1112009023390309/17/09 Azetidine and cyclobutane derivatives as jak inhibitors
1122009021576608/27/09 Tetracyclic inhibitors of janus kinases
1132009019788708/06/09 Piperazinylpiperidine derivatives as chemokine receptor antagonists
1142009018195907/16/09 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1152009012464905/14/09 Aza spiro alkane derivatives as inhibitors of metalloproteases
1162009008844604/02/09 Purinone derivatives as hm74a agonists
1172009007626903/19/09 Purinone derivatives as hm74a agonists
1182012026367610/18/12 Compositions, methods and kits relating to her-2 cleavage
1192012005807903/08/12 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
1202012001498901/19/12 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1212011031147912/22/11 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
1222011022321009/15/11 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1232011022415709/15/11 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1242011017227907/14/11 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1252011016518807/07/11 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1262011008683504/14/11 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1272009029880812/03/09 Inhibitors of 11-beta hydroxyl steroid dehydrogenase type i and methods of using the same
1282009019786908/06/09 Azepine inhibitors of janus kinases



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Incyte Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Incyte Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE